Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pod will skyrocket upon clinical update news anyday
PR is overdue now
I agree
Let’s see what happen this week
I expect the P1 clinical update news this week or next week
Pancreatic cancer treatment mean billion dollars potential
The fair market value is more than $100 mil
for human P1 clinical trial here
1000% easy
I play other nasdaq ticker
This one looks very undervalued now
I will add more
I see $26 mil asset valuation here
just $1 mil mktcap is ridiculous
waiting for huge clinical update news now
Good luck
1000% explosion upon clinical trial news anyday imo
Looks interesting here
Everything point to FDA AA is coming this year
I will wait for 1000% profit this year
Huge news indeed
Looks like Accelerated Approval is given sooner
CAPR
Another nice news now
1000% runner in the making
FDA AA is coming soon
Patience will pay off huge soon this year
DMD FDA AA means more than $2 billion dollars mktcap
Exosome platform is worth multi billion dollars as well
I believe $100 coming this year and $200 next year
This is once in a life time chance
The current Pps is a gift
CAPR
huge explosion
Mega deal with big phama for Exosome platform coming
$5 breaking now
Huge news on the way
Mega deal with big pharm?
The time has come
SRPT is valued over $10 billion
We are heading to $1 billion mktcap soon
CAPR
Exploding like another DMD treating bio play
FDA news is very close
$2 billion revenue for DMD
Big news coming on ER next week
$6 coming after ER next week
Another DMD bio ticker SRPT is soaring to New high valued over $10 billion now
CAPR is the next big runner
CAPR
keep going up everyday
The most undervalued and safest bio play
1000% increase expected soon
Billion dollars revenue upon DMD AA
BLA will be filed this summer
CAPR
Insiders keep buying shares
Huge news coming
1000% profit on the way upon AA
CAPR
Insiders keep buying shares
Huge news pending here
CAPR will be valued about $500 mil upon BLA submission and $2 billion upon Accelerated approval
How about Exosome platform partnership with big pharm?
I believe $100 pps is coming in this year
CAPR will be top gainer this year
1000% increase
$6 coming again
This additional partnership by Nippon Shinyaku show huge confidence for FDA AA coming this summer
You bet
The journey is just beginning
Nippon Shinyaku is big Japanese pharmaceutical company and expert in DMD
They believe FDA AA is given this summer
So much undervalued and huge short squeeze
CAPR keep going up now
Huge additional partnership
FDA Accelerated Approval is coming soon
$100 upon FDA AA
Toru Nakai, President of Nippon Shinyaku, commented, "We look forward to further strengthening our partnership with Capricor as CAP-1002 moves towards potential commercialization. This agreement provides an opportunity to expand Nippon Shinyaku's DMD franchise and to advance potentially life-changing therapies for patients with Duchenne Muscular Dystrophy. In Japan, we already have launched Viltepso(R), an exon skipping agent for the treatment of DMD and will leverage our established commercial infrastructure to deliver on our shared mission of bringing hope to more patients with the addition of CAP-1002 to our pipeline."
Pps will keep going up now
Huge ER in a few weeks
Short squeeze is coming now
This additional partnership solidify FDA AA is coming soon
I believe we see $100 upon FDA accelerated approval this year
BLA submission coming very soon
That is why NS making partnership
They know AA is inevitable this summer
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
Mentioned: CAPR
GlobeNewswireFebruary 16, 2023
-Expands Partnership with Nippon Shinyaku to Japan to Leverage Deep Experience in Drug Development for Rare Diseases and Commercial DMD Franchise-
-Capricor to Receive an Upfront Payment of $12 Million, Additional Potential Milestone
Payments of up to $89 Million as well as Meaningful Double-Digit Percentage of Revenue Based on Product Sales-
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that it has entered into a partnership with Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company listed on the TYO, for the exclusive commercialization and distribution in Japan of Capricor's lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD), a rare neuromuscular disease with limited treatment options. This follows the exclusive Commercialization and Distribution Agreement entered into with Nippon Shinyaku in the United States in January 2022.
"Nippon Shinyaku is a proven leader in developing therapeutics for rare diseases, specifically DMD, and an ideal partner for us to maximize the opportunity with CAP-1002 in Japan and the U.S.," said Dr. Linda Marban, CEO of Capricor. "With the addition of non-equity capital from this transaction, we are well positioned to advance and execute on our milestones including the execution of the HOPE-3 Phase 3 trial in the United States. CAP-1002 has shown clinical benefits for both the cardiac and skeletal muscle myopathy, which few therapies have demonstrated. The data from our recently announced 18-month HOPE-2 open label extension study showed evidence of disease modification and showed statistically significant differences in the Performance of the Upper Limb (PUL). This continues to build upon CAP-1002's safety and efficacy profile and to potentially establish it as an anchor therapy for DMD patients. Furthermore, we remain committed to securing strategic partners that will further strengthen our balance sheet and help us achieve our goal of bringing our therapies to the global patient community as quickly as possible."
Under the terms of the agreement, Capricor will receive an upfront payment of $12 million and in addition, Capricor will potentially receive additional development and sales-based milestone payments of up to approximately $89 million and a meaningful, double-digit share of product revenue. This agreement is similar to the terms of the U.S. agreement with Nippon Shinyaku, in that Capricor will be responsible for clinical development and Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan, once approved. Capricor will sell commercial product to Nippon Shinyaku. In addition, Capricor will hold the Marketing Authorization in Japan, if the product is approved in that territory.
Toru Nakai, President of Nippon Shinyaku, commented, "We look forward to further strengthening our partnership with Capricor as CAP-1002 moves towards potential commercialization. This agreement provides an opportunity to expand Nippon Shinyaku's DMD franchise and to advance potentially life-changing therapies for patients with Duchenne Muscular Dystrophy. In Japan, we already have launched Viltepso(R), an exon skipping agent for the treatment of DMD and will leverage our established commercial infrastructure to deliver on our shared mission of bringing hope to more patients with the addition of CAP-1002 to our pipeline."
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a devastating genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart and respiratory muscles. Patients suffering from DMD typically lose their ability to walk in their teenage years and generally die of cardiac or respiratory complications by age 30. It occurs in one in every 3,600 live male births across all races, cultures and countries. DMD afflicts approximately 200,000 boys and young men around the world. Treatment options are limited and there is no cure.
About CAP-1002
CAP-1002 consists of allogeneic cardiosphere-derived cells (CDCs), a type of progenitor cell that has been shown in pre-clinical and clinical studies to exert potent immuno-modulatory activity and is being investigated for its potential to modify the immune system's activity to encourage cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials.
About Nippon Shinyaku
Based on Nippon Shinyaku's business philosophy, "Helping people lead healthier, happier lives," we aim to be an organization trusted by the community through creating unique medicines that will bring hope to patients and families suffering from illness. Please visit our website (https://www.nippon-shinyaku.co.jp/english/) for products or detailed information.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's focus is on developing exosomes capable of delivering nucleic acids, including mRNA, as well as proteins to treat or prevent a variety of diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and Twitter.
CAPR
Huge news out!
CAPR will explode to $100 this year
I am long in this 1000% runner this year
https://stocktwits.com/Stonksgoingup/message/509162017